Oriol Rodriguez-Queralto

Oriol Rodriguez-Queralto

Auto-generated profile, based on publicly available information

Oriol Rodriguez-Queralto

Hospital del Mar and Hospital del Mar Research Institute Barcelona Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
CMCarlos Eduardo González Matos
Carlos Eduardo González Matos
OROriol Rodríguez-Queralto
Oriol Rodríguez-Queralto
FZFátima Záraket
Fátima Záraket
JJJesús Jiménez
Jesús Jiménez
BCBenjamín Casteigt
Benjamín Casteigt
EVErmengol Valles
Ermengol Valles
BACKGROUND: Right ventricular apical pacing (RVAP) can produce left ventricle dysfunction. Conduction system pacing (CSP) has been used successfully to reverse left ventricle dysfunction in patients with left bundle branch block. To date, data about CSP prevention of left ventricle dysfunction in patients with preserved left ventricular ejection fraction (LVEF) are scarce and limited mostly to nonrandomized studies. Our aim is to demonstrate that CSP can preserve normal ventricular function compared with RVAP in the setting of a high burden of ventricular pacing. METHODS: Consecutive patients with a high-degree atrioventricular block and preserved or mildly deteriorated LVEF (>40%) were included in this prospective, randomized, parallel, controlled study, comparing conventional RVAP versus CSP. RESULTS: Seventy-five patients were randomized, with no differences between basal characteristics in both groups. The stimulated QRS duration was significantly longer in the RVAP group compared with the CSP group (160.4±18.1 versus 124.2±20.2 ms; p <0.01). Seventy patients were included in the intention-to-treat analyses. LVEF showed a significant decrease in the RVAP group at 6 months compared with the CSP group (mean difference, −5.8% [95% CI, −9.6% to −2%]; P <0.01). Left ventricular end-diastolic diameter showed an increase in the RVAP group compared with the CSP group (mean difference, 3.2 [95% CI, 0.1–6.2] mm; P =0.04). Heart failure–related admissions were higher in the RVAP group (22.6% versus 5.1%; P =0.03). CONCLUSIONS: Conduction system stimulation prevents LVEF deterioration and heart failure–related admissions in patients with normal or mildly deteriorated LVEF requiring a high burden of ventricular pacing. These results are only short term and need to be confirmed by further larger studies. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06026683.

3 June 2025 in EP Europace
Verified
Journal Article
Open access
AOAlireza Oraii
Alireza Oraii
BHBalaram Krishna Jagannayakulu Hanumanthu
Balaram Krishna Jagannayakulu Hanumanthu
APAdrian Petzl
Adrian Petzl
TLTing-Wei Ernie Liao
Ting-Wei Ernie Liao
AAArian Afzalian
Arian Afzalian
FMFrancis E Marchlinski
Francis E Marchlinski
Aims: The diagnosis of infiltrative cardiomyopathies has increased over last years. Catheter ablation is becoming the preferred approach for managing atrial fibrillation (AF) in these patients. This study aims to characterize differences in procedural findings during AF ablation in patients with and without infiltrative cardiomyopathies. Methods and results: Patients with cardiac amyloidosis and cardiac sarcoidosis undergoing first-time AF ablation were propensity score matched in 1:4 ratio to separate reference groups that received trigger provocative manoeuvres (isoproterenol infusion and/or atrial burst pacing) and had no prior cardiac surgery. Non-pulmonary vein (PV) triggers [defined as ectopic foci initiating AF or sustained focal atrial tachycardia (AT)] and macro-reentrant atrial flutters (AFLs) were then mapped and targeted. Recurrence was defined as AF/AT/AFL ≥ 30 s after 90-day blanking period. Twenty-four patients with cardiac amyloidosis were matched to 96 controls, and 17 patients with cardiac sarcoidosis were matched to 68 controls. Non-PV triggers were more frequent in patients with cardiac amyloidosis {29.2% vs. 8.3%; odds ratio [OR] = 4.5 [95% confidence interval (CI): 1.4–14.2]} and cardiac sarcoidosis [17.6% vs. 7.4%; OR = 2.7 (95% CI: 0.6–12.6)] compared with their reference groups. Patients with cardiac amyloidosis also had a higher incidence of left atrial macro-reentrant flutters [37.5% vs. 6.3%; OR = 9.0, (95% CI: 2.8–29.0)]. One-year recurrence rate was similar between patients with cardiac sarcoidosis and controls (33.3% vs. 33.9%; P = 0.965) but higher in patients with cardiac amyloidosis vs. controls (47.4% vs. 27.1%; P = 0.049). Conclusion: Patients with infiltrative cardiomyopathies exhibit higher rates of non-PV triggers and left AFLs during first-time AF ablation. Those with cardiac amyloidosis experience higher arrhythmia recurrence rates compared with controls.

2 January 2026 in European Journal of Neurology
Verified
Journal Article
Open access
EVErmengol Valles
Ermengol Valles
AGA. B. Garcia
A. B. Garcia
EGE. Giralt‐Steinhauer
E. Giralt‐Steinhauer
MBM. Ble
M. Ble
JJJ. I. Jiménez
J. I. Jiménez
MCM. Cainzos‐Achirica
M. Cainzos‐Achirica
Background: Cryptogenic strokes (CS) represent one third of admissions for stroke. Silent paroxysmal atrial fibrillation (PAF) is the underlying cause of a significant proportion of cases. The use of internal loop recorders (ILR) after CS has shown controversial results, remaining unclear in guidelines. Subtle ultrasound left atrium (LA) anomalies may help select patients more prone to suffer from silent PAF who can benefit from an ILR. Methods: Randomized, controlled, parallel‐arm, open‐label trial of patients with CS. We evaluated the efficacy of early ILR for detection of silent PAF episodes compared to standard care. Clinical/ultrasound predictors of PAF were studied. The presence of subtle LA anomalies (any of: LA dilatation, maximum systolic global longitudinal strain < 21%, atrial contraction strain < 13%, atrial ejection fraction < 55%) was used in a pre‐specified subgroup analysis. Results: Fifty‐nine CS patients were included (52.5% to ILR and 47.5% to standard care). There were no statistically significant differences among groups regarding baseline characteristics. Median follow‐up was 377 days. The diagnosis of silent PAF was made in 43.3% in the ILR group compared to 7.1% in the control group (HR 7.47, 95% CI 1.68–31.19, p = 0.008). Most PAF events were detected in the 100 days following ILR implantation. In patients with normal LA, PAF was observed in 23% versus 7%, while in patients with abnormal LA, PAF was diagnosed in 58.8% versus 7.7%. Conclusions: An ILR implanted early after CS improves the detection of PAF compared to standard care. Individuals with abnormal LA features may benefit the most from ILR.

8 October 2026 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Open access
AAArian Afzalian
Arian Afzalian
AOAlireza Oraii
Alireza Oraii
CCCorentin Chaumont
Corentin Chaumont
OROriol Rodriguez-Queralto
Oriol Rodriguez-Queralto
YSYuichiro Sagawa
Yuichiro Sagawa
FMFrancis E. Marchlinski
Francis E. Marchlinski
BACKGROUND: Patients with nonischemic cardiomyopathy (NICM) and ventricular tachycardia are at increased risk for adverse HF outcomes, and abnormal left ventricular (LV) substrate identified by endocardial unipolar and bipolar low-voltage areas (LVAs) may aid in risk stratification. This study assessed the association of LV unipolar and bipolar LVAs with end-stage HF outcomes in patients with NICM undergoing ventricular tachycardia ablation. METHODS: Patients with NICM and LV ejection fraction (EF) 2 cm 2 ) unipolar LVAs as <8.27 mV and bipolar LVAs as <1.5 mV during sinus or paced rhythm. End-stage HF outcomes included HF death, LV assist device implantation, or heart transplant. Multivariable Cox proportional hazards regression analysis assessed associations between unipolar/bipolar LVAs and end-stage HF outcomes. RESULTS: One hundred eleven patients with NICM (mean age, 64.6±9.8 years; 81.1% male; mean LVEF, 33.8±11.7%) were included. During a median follow-up of 28.1 months (interquartile range, 18–46), 28 (25.2%) patients experienced end-stage HF outcomes. Unipolar LVA (hazard ratio, 1.03 per 1% increase [95% CI, 1.01–1.05]; P =0.002) and LVEF (hazard ratio, 1.04 per 1% decrease [95% CI, 1.00–1.09]; P =0.03) were independently associated with higher end-stage HF risk, while bipolar LVA was not (hazard ratio, 0.98, 1% increase [95% CI, 0.96–1.01]; P =0.25). A 3-point risk score based on the Youden index, unipolar LVA ≥70% (2 points), 35% to 70% (1 point), and LVEF ≤25% (1 point), had 82.1% sensitivity and 77.1% specificity for predicting end-stage HF in scores ≥2. CONCLUSIONS: In patients with NICM undergoing ventricular tachycardia ablation, unipolar LVA and LVEF are independent predictors of end-stage HF outcomes. Integrating these predictors yields a prognostic score to identify patients at the highest risk of end-stage HF outcomes.